Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gilles Salles1, Pierre Sesques1, Emmanuelle Ferrant2

  • 1Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, 69495 Pierre Bénite cedex, France; Université Claude Bernard Lyon-1, 69100 Villeurbanne, France.

Bulletin Du Cancer
|January 29, 2019
PubMed
Summary

Chimeric antigen receptor (CAR-T) therapy shows promise for aggressive B-cell lymphoma, with significant tumor response rates. Ongoing research aims to refine CAR-T cell treatments for improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Journal of geriatric oncology·2026
Same author

CAR in R/R FL: is real-world efficacy meeting expectations?

Blood advances·2026
Same author

Marginal Zone Lymphoma With T-Follicular Helper Hyperplasia: Paving the Way for New Concepts in Cellular Plasticity and Unveiling Histopathologic Pitfalls.

The American journal of surgical pathology·2026
Same author

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.

Cancer·2026
Same author

Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression.

Nature communications·2026
Same author

Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphoma.

Leukemia & lymphoma·2026

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Chimeric antigen receptor (CAR-T) therapy targeting CD19 has emerged as a promising treatment for lymphoma.
  • Recent clinical trials have evaluated the efficacy and safety of CAR-T cell therapies in patients with relapsed or refractory aggressive B-cell lymphoma.

Purpose of the Study:

  • To assess the efficacy and safety of CD19-directed CAR-T cell therapy in aggressive B-cell lymphoma.
  • To review the outcomes of major clinical trials (Zuma-1, Juliet, Transcend) evaluating CAR-T cell therapy.
  • To discuss the potential role of CAR-T cell therapy in the evolving treatment landscape for lymphoma.

Main Methods:

  • Review of data from three major clinical trials (Zuma-1, Juliet, Transcend) involving CAR-T cell therapy for lymphoma.
Keywords:
Cell therapyGene therapyImmunotherapyImmunothérapieLymphomaLymphomeThérapie cellulaireThérapie génique

Related Experiment Videos

  • Analysis of tumor response rates, including complete response (CR) and partial response (PR).
  • Evaluation of treatment-related toxicities, such as cytokine release syndrome and neurological events.

    • Main Results:

    • Tumor response rates ranged from 52% to 82%, with best complete response (CR) rates between 40% and 58%.
    • Prolonged CR was observed in 30% to 40% of patients, with responses improving over time for some.
    • Key toxicities included cytokine release syndrome (1% to 22%) and neurological disorders (12% to 31%), mostly reversible.

    Conclusions:

    • CAR-T cell therapy demonstrates significant efficacy in treating aggressive B-cell lymphoma.
    • While toxicities are manageable, careful monitoring and management are essential.
    • Further research and development are crucial to optimize CAR-T cell therapy's role in lymphoma treatment strategies.